Institut Jules Bordet

Futó vizsgálatok

• Még nem toboroz

  Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations

  NCT07738887· 2. fázis· Forrás

• Még nem toboroz

  Antibody-based PET Imaging and Treatment Response in Breast Cancer Treated With an Antibody-drug Conjugate.

  NCT07294430· 2. fázis· Forrás

• Még nem toboroz

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· 3. fázis· Forrás

• Toboroz

  A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours

  2025-521164-36-00· 1/2. fázis· Forrás

• Toboroz

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· 3. fázis· Forrás

• Még nem toboroz

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· 3. fázis· Forrás

• Toboroz

  A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer

  NCT07693751· 1/2. fázis· Forrás

• Még nem toboroz

  Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy

  2025-523575-36-00· 2. fázis· Forrás

• Toboroz

  Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study

  NCT06990061· Forrás

• Még nem toboroz

  Microwave Intervention Under Local Anesthesia

  NCT07412275· Forrás

• Fut, nem toboroz

  Holistic Evaluation of Approaches to Long-term Health & Survivorship

  NCT07745205· Forrás

• Toboroz

  Immune Fitness in Older Patients With Relapsed and Refractory Multiple Myeloma

  NCT07674498· Forrás

• Toboroz

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· 3. fázis· Forrás

• Toboroz

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· 3. fázis· Forrás

• Toboroz

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· 2/3. fázis· Forrás

• Toboroz

  Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

  NCT07531095· 1. fázis· Forrás

• Toboroz

  Radiopharmaceutical Treatment of Advanced Kidney Cancer

  NCT06783348· 2. fázis· Forrás

• Toboroz

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· 3. fázis· Forrás

• Toboroz

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· 3. fázis· Forrás

• Toboroz

  Biopsy-Resection Agreement of Peritoneal Histopathological Growth Patterns in Colorectal Peritoneal Metastases: A Prospective Observational Pilot Study

  NCT07474025· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Forrás

• Toboroz

  A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  NCT07318558· 3. fázis· Forrás

• Fut, nem toboroz

  Prophylactic Intervention for Dysgeusia in Head and Neck Cancer Patients Following Radio(Chemo)Therapy

  NCT07431346· Forrás

• Toboroz

  LUtetium-177 DOsimetry as a Predictive Biomarker of Response in Metastatic Prostate Cancer Patients Treated With PSMA Radioligand THerapy.

  NCT07370597· Forrás

• Toboroz

  Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

  NCT07288177· 2. fázis· Forrás

• Toboroz

  Ventral Hernias Following Cytoreductive Surgery : Incidence, Risk Factors and Surgical Management.

  NCT07451483· Forrás

• Toboroz

  LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor

  NCT04939610· 2. fázis· Forrás

• Toboroz

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· 3. fázis· Forrás

• Toboroz

  A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07155187· 2/3. fázis· Forrás

• Toboroz

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· 3. fázis· Forrás

• Toboroz

  Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

  NCT07281833· 3. fázis· Forrás

• Toboroz

  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  NCT06996782· 1/2. fázis· Forrás

• Toboroz

  A clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)

  2024-511392-15-00· 3. fázis· Forrás

• Toboroz

  A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07023627· 2. fázis· Forrás

• Toboroz

  Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

  NCT06925984· Forrás

• Toboroz

  Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI-SAVE

  2024-514693-47-01· 4. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· 2/3. fázis· Forrás

• Toboroz

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· 3. fázis· Forrás

• Toboroz

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· 2/3. fázis· Forrás

• Toboroz

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  NCT06973187· 3. fázis· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Forrás

• Toboroz

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· 1/2. fázis· Forrás

• Toboroz

  A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia (AML) with a specific gene abnormality who have not previously been treated and who are not eligible for intensive chemotherapy.

  2024-512753-24-00· 3. fázis· Forrás

• Toboroz

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· 3. fázis· Forrás

• Toboroz

  Molecular Imaging of Cancer-associated Fibroblasts in Glioblastoma: a FAPI PET/MR Study.

  NCT07119294· Forrás

• Toboroz

  Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  NCT07044336· 3. fázis· Forrás

• Toboroz

  Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

  NCT06606730· 3. fázis· Forrás

• Toboroz

  Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

  NCT06943755· 2/3. fázis· Forrás

• Toboroz

  Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

  2023-510356-23-00· 1. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Vastagbélrák24 toboroz
• Tüdőrák21 toboroz
• Áttétes emlőrák19 toboroz
• Hasnyálmirigyrák14 toboroz
• Prosztatarák12 toboroz
• Fej-nyaki daganatok11 toboroz
• Petefészekrák10 toboroz
• Gyomor- és nyelőcsőrák8 toboroz
• Tripla negatív emlőrák8 toboroz
• Méhtestrák7 toboroz
• Mielóma multiplex6 toboroz
• Akut mieloid leukémia (AML)5 toboroz
• Gyermekkori daganatok5 toboroz
• Krónikus limfoid leukémia (CLL)4 toboroz
• Melanóma4 toboroz
• Vesedaganat4 toboroz
• Hólyagrák3 toboroz
• Akut limfoid leukémia (ALL)2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Follikuláris limfóma2 toboroz
• Glioblasztóma2 toboroz
• Köpenysejtes limfóma2 toboroz
• Krónikus mieloid leukémia (CML)2 toboroz
• Hodgkin-limfóma1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhnyakrák1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mieloproliferatív neopláziák1 toboroz
• Neuroendokrin daganatok1 toboroz
• Szarkóma1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

  NCT06595563· 2. fázis· Forrás

• Lezárult

  A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC

  2025-522867-13-00· 2. fázis· Forrás

• Lezárult

  A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

  2025-521480-12-00· 1. fázis· Forrás

• Fut, nem toboroz

  Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer

  NCT06840483· 2. fázis· Forrás

• Fut, nem toboroz

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

  NCT06632951· 2. fázis· Forrás

• Visszavonták

  A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors

  NCT06411301· 1. fázis· Forrás

• Lezárult

  TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of vepdegestrant (ARV-471) in Combination With Other Medicines in Adults With ER+ Advanced or Metastatic Breast Cancer, Sub-study C (ARV-471 and Samuraciclib)

  NCT06125522· 1/2. fázis· Forrás

• Fut, nem toboroz

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· 3. fázis· Forrás

• Toboroz

  A trial to learn how effective and safe odronextamab is compared to standard of care for adult participants with previously treated aggressive B-cell Non-Hodgkin Lymphoma.

  NCT06230224· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· 2. fázis· Forrás

• Lezárult

  (VELA) Study of BLU-222 in Advanced Solid Tumors

  NCT05252416· 1/2. fázis· Forrás

• Toboroz

  A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

  NCT06091254· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· 3. fázis· Forrás

• Lezárult

  A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

  NCT05487248· Forrás

• Leállították

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· 2. fázis· Forrás

• Lezárult

  PROstate CAncer Radiotherapy - Bowel Quality of Life (PROCAR-BQ)

  NCT05880446· Forrás

• Lezárult

  A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)

  2022-502057-33-00· 1/2. fázis· Forrás

• Lezárult

  Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)

  NCT05882734· 1/2. fázis· Forrás

• Lezárult

  A study to investigate response to ompenaclid combined with FOLFIRI plus bevacizumab in patients with advanced or metastatic colorectal cancer

  2023-503356-27-00· 2. fázis· Forrás

• Fut, nem toboroz

  Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

  NCT05673187· 2. fázis· Forrás

• Lezárult

  First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

  2022-501183-17-00· 1/2. fázis· Forrás

• Lezárult

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· 2. fázis· Forrás

• Lezárult

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· 3. fázis· Forrás

• Lezárult

  Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone (FORTITUDE-102)

  NCT05111626· 3. fázis· Forrás

• Lezárult

  Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma (CLAUDIO-01)

  NCT05525286· 1/2. fázis· Forrás

• Leállították

  A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

  NCT05256381· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

  NCT05307705· 1. fázis· Forrás

• Leállították

  Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

  NCT05289492· 1. fázis· Forrás

• Fut, nem toboroz

  A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors

  NCT05143970· 1. fázis· Forrás

• Fut, nem toboroz

  Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).

  NCT05116189· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

  NCT05091567· 3. fázis· Forrás

• Leállították

  Study of INCA 0186 in Subjects With Advanced Solid Tumors

  NCT04989387· 1. fázis· Forrás

• Leállították

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· 1/2. fázis· Forrás

• Lezárult

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· 3. fázis· Forrás

• Lezárult

  Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

  NCT04925284· 1. fázis· Forrás

• Leállították

  Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

  NCT04868877· 1/2. fázis· Forrás

• Leállították

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

  NCT04272034· 1. fázis· Forrás

• Lezárult

  Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

  NCT04697628· 3. fázis· Forrás

• Lezárult

  Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)

  2024-511140-37-00· 2. fázis· Forrás

• Lezárult

  Efficacy Assessment of a Novel 3D Cartography-based Targeted Focal Microwave Therapy in Men With Localized Intermediate-risk Prostate Cancer

  NCT04582656· Forrás

• Lezárult

  Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1)

  NCT04797780· 3. fázis· Forrás

• Lezárult

  Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.

  NCT04463771· 2. fázis· Forrás

• Fut, nem toboroz

  A study of tucatinib vs. placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with advanced or metastatic HER2+ breast cancer

  NCT03975647· 3. fázis· Forrás

• Lezárult

  Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy

  NCT04471428· 3. fázis· Forrás

• Lezárult

  A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)

  NCT04458831· Forrás

• Leállították

  Futibatinib in Patients With Specific FGFR Aberrations

  NCT04189445· 2. fázis· Forrás

• Lezárult

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· 3. fázis· Forrás

• Lezárult

  Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients

  NCT04379817· 2. fázis· Forrás

• Lezárult

  Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

  NCT03993912· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)

  NCT04008030· 3. fázis· Forrás

Vizsgálati helyszínek

• Institut Jules Bordet176 vizsgálat
• Institut Jules Bordet - Department of Institut Jules Bordet'0 vizsgálat
• Institut Jules Bordet - HUB0 vizsgálat
• Institut Jules Bordet /ID# 2259540 vizsgálat
• Institut Jules Bordet /ID# 2386140 vizsgálat
• Institut Jules Bordet /ID# 2467700 vizsgálat
• Institut Jules Bordet /ID# 2546760 vizsgálat
• Institut Jules Bordet /ID# 2576250 vizsgálat
• Institut Jules Bordet /ID# 2772830 vizsgálat
• Institut Jules Bordet /ID# 2794060 vizsgálat
• Institut Jules Bordet - Investigational Site Number : 05600011 vizsgálat
• Institut Jules Bordet / Nuclear Medicine0 vizsgálat
• Institut Jules Bordet - Oncologie Médicale0 vizsgálat
• Institut Jules Bordet (Site 1103)1 vizsgálat
• Jules Bordet Institut0 vizsgálat
• Jules Bordet Institute1 vizsgálat
• Jules Bordet Instituut0 vizsgálat
• Universite Libre de Bruxelles (ULB)-Institut Jules Bordet1 vizsgálat
• Institute Jules Bordet3 vizsgálat
• Institut Jules Bordet81 vizsgálat
• Institut Jules Bordet - Centre des tumeurs de l'ULB1 vizsgálat
• Institut Jules Bordet - Department of Intensive Care and Thoracic Oncology1 vizsgálat
• Institut Jules Bordet (JBI)1 vizsgálat
• Institut Jules Bordet/Jules Bordet Instituut1 vizsgálat
• Institut Jules Bordet - Medical Oncology1 vizsgálat
• Institut Jules Bordet - Oncologie Médicale1 vizsgálat
• INSTITUT JULES BORDET - Service Hématologie1 vizsgálat
• Institut Jules Bordet (Site 0254)0 vizsgálat
• Institut Jules Bordet (Site 0480)0 vizsgálat
• Jules Bordet Institute6 vizsgálat
• Jules Bordet Institute, H.U.B1 vizsgálat
• Jules Bordet Institute, HUB0 vizsgálat
• Universite Libre de Bruxelles (ULB) - Institut Jules Bordet0 vizsgálat
• Institut Jules Bordet1 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Tripla negatív emlőrák24 munka · 17 vizsgálat
• Áttétes emlőrák14 munka · 46 vizsgálat